Review
Published · Updated · 1 min read
Rituximab-based combination therapy for lymphoma involving cerebrospinal fluid: improvement in a reported case
What it means for practice
This case illustrates the potential of combined systemic and intrathecal therapy for this rare lymphoma presentation, but does not establish a treatment standard.
Summary
Clinical presentation and diagnosis
A case describes secondary cerebrospinal fluid involvement by extranodal marginal zone lymphoma of the salivary gland in an 82-year-old woman. Initially asymptomatic, the patient subsequently developed neurological symptoms. The diagnosis was established using flow cytometry. The publication title specifies that the sample examined was paucicellular.
Treatment and outcome
The patient received systemic immunochemotherapy with rituximab and cyclophosphamide combined with intrathecal methotrexate, cytarabine, and dexamethasone. Treatment was followed by significant improvement in neurological symptoms and disappearance of atypical cells from the cerebrospinal fluid. The reported outcome concerns the combined treatment rather than any individual drug.
Clinical relevance and limits of the data
The authors highlight the potential of combined systemic and intrathecal therapy for this rare lymphoma presentation. However, the report concerns a single patient. The abstract does not provide doses, the number of treatment courses, time to improvement, or follow-up duration; it also provides no quantitative assessment of the neurological response.
Source
-
A rare case of secondary cerebrospinal fluid involvement by extranodal marginal zone lymphoma of the salivary gland diagnosed in a paucicellular sample by flow cytometry.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer